Dixon Mitchell Investment Counsel Inc. Gilead Sciences, Inc. Transaction History
Dixon Mitchell Investment Counsel Inc.
- $2.16 Trillion
- Q4 2024
A detailed history of Dixon Mitchell Investment Counsel Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Dixon Mitchell Investment Counsel Inc. holds 76 shares of GILD stock, worth $7,071. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76Holding current value
$7,071% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
1,940Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.2 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.7 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.12 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.75 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.6 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $117B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...